Clinical Trial Update: Enzalutamide vs. Abiraterone in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC)

View source ↗

Summary

Pfizer-sponsored head-to-head trial in chemotherapy-naïve metastatic castration-resistant prostate cancer comparing enzalutamide to abiraterone has completed an…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Xtandi (enzalutamide)
• Zytiga (abiraterone acetate)

Snippet

Sponsor: Pfizer | Conditions: Prostatic Neoplasms, Castration-Resistant | Status: COMPLETED | Results posted: 2024-09-27